Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

WEST PHARMACEUTICAL SERVICES INC Director's Dealing 2022

Dec 8, 2022

30339_dirs_2022-12-08_ce324dfa-b4db-4377-ab29-25b4396809be.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: WEST PHARMACEUTICAL SERVICES INC (WST)
CIK: 0000105770
Period of Report: 2022-12-05

Reporting Person: Green Eric Mark (N/A)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2022-12-05 Common Stock M 50000.00 $57.38 Acquired 158922.0865 Direct
2022-12-05 Common Stock S 6746.00 $236.9488 Disposed 152176.0865 Direct
2022-12-05 Common Stock S 9408.00 $237.6676 Disposed 142768.0865 Direct
2022-12-05 Common Stock S 6312.00 $238.8268 Disposed 136456.0865 Direct
2022-12-05 Common Stock S 10752.00 $239.6972 Disposed 125704.0865 Direct
2022-12-05 Common Stock S 9682.00 $240.7328 Disposed 116022.0865 Direct
2022-12-05 Common Stock S 1100.00 $241.4645 Disposed 114922.0865 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2022-12-05 Stock Option (Right to Buy) $57.38 M 50000.00 Disposed 2025-04-24 Common Stock (50000.00) Direct

Footnotes

F1: The shares reported were acquired by the Reporting Person from exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was completed pursuant to a Rule 10b5-1 Trading Plan adopted by the Reporting Person on 9/14/2022.

F2: This transaction was effective pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on 9/14/2022. The Rule 10b5-1 trading plan, which was structured to include several sale periods, was established as part of the Reporting Person's long-term strategy for asset diversification and financial, retirement, estate and tax planning activities over a period of time.

F3: The price reported in Column 4 is an average price. These shares were purchased in multiple transactions at prices ranging from $236.255 to $237.245, inclusive. The reporting person undertakes to provide to West Pharmaceutical Services, Inc., any security holder of West Pharmaceutical Services, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range in this footnote.

F4: The price reported in Column 4 is an average price. These shares were purchased in multiple transactions at prices ranging from $237.255 to $238.21, inclusive. The reporting person undertakes to provide to West Pharmaceutical Services, Inc., any security holder of West Pharmaceutical Services, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range in this footnote.

F5: The price reported in Column 4 is an average price. These shares were purchased in multiple transactions at prices ranging from $238.26 to $239.25, inclusive. The reporting person undertakes to provide to West Pharmaceutical Services, Inc., any security holder of West Pharmaceutical Services, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range in this footnote.

F6: The price reported in Column 4 is an average price. These shares were purchased in multiple transactions at prices ranging from $239.26 to $240.25, inclusive. The reporting person undertakes to provide to West Pharmaceutical Services, Inc., any security holder of West Pharmaceutical Services, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range in this footnote.

F7: The price reported in Column 4 is an average price. These shares were purchased in multiple transactions at prices ranging from $240.29 to $241.27, inclusive. The reporting person undertakes to provide to West Pharmaceutical Services, Inc., any security holder of West Pharmaceutical Services, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range in this footnote.

F8: The price reported in Column 4 is an average price. These shares were purchased in multiple transactions at prices ranging from $241.33 to $241.56, inclusive. The reporting person undertakes to provide to West Pharmaceutical Services, Inc., any security holder of West Pharmaceutical Services, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range in this footnote.

F9: This option is fully vested.